Pediatric Oncology & Neuroblastoma Clinical Research
Pediatric oncology trials require a unique ethical and operational approach. Ergomed combines rare disease expertise with compassionate site management to support families and children. We navigate the complexities of pediatric formulations and regulatory incentives (like Priority Review Vouchers) to advance life-saving therapies.
Specialized Global CRO Support for Rare and High-Risk Cancers
With global infrastructure and dedicated oncology teams, we support multi-phase neuroblastoma studies, including trials involving immunotherapies, biologics, cell and gene therapies, and complex combination regimens.
Patient Centricity in Pediatric Oncology
At Ergomed, patient centricity is not an add-on, it is the foundation of how we design and deliver pediatric oncology studies. From protocol development to post-trial follow-up, we focus on creating an experience that supports children, their families, and the wider care community.
Family-Focused Support
Ensuring parents and guardians receive clear, accessible, and empathetic information.
Patient Advocacy Partnerships
Collaborating with national and local groups to build trust, raise awareness, and improve diversity in recruitment.
Tailored Trial Design
Balancing scientific rigor with the realities of pediatric patient needs, such as reduced hospital visits, simplified documentation, and age-appropriate communication.
Holistic Engagement
Working with teachers, community leaders, and healthcare providers to support children beyond the study site.
Early Stage Development in Rare Pediatric Oncology
By combining regulatory expertise, a collaborative approach, and a tailored development strategy, Ergomed helped secure clearance to begin a Phase I trial that was both scientifically rigorous and ethically sound.
Supporting the Entire Patient Network
By addressing the critical touchpoints across the patient journey, this webinar highlights how sponsors can strengthen trust, enhance engagement, and ultimately drive more efficient and patient-centric outcomes in clinical trials.
Turning Rare Diagnoses into Research Breakthroughs
Leveraging global reach, established partnerships with leading pediatric oncology centers, and multidisciplinary expertise, Ergomed ensures operational excellence and scientific rigor in every study.
Proven Expertise in Neuroblastoma and Pediatric Cancer Trials:
- Experience in rare pediatric oncology studies, including neuroblastoma, Wilms tumor, and medulloblastoma
- Expertise across Phase I–III studies, including dose-escalation and cohort-based designs
- Strong relationships with pediatric oncology centers and academic hospitals
- Multidisciplinary oversight teams with pediatric, regulatory, and pharmacovigilance expertise
- Global reach across 50+ countries and 3,800+ active sites
- Patient-centric approach to ensure family support, compliance, and retention
Therapeutic Expertise Backed by Operational Excellence
Ergomed has managed over 470 oncology trials globally, including numerous pediatric programs involving novel therapeutic platforms such as CAR-T, radiopharmaceuticals, and monoclonal antibodies.
We are adept at executing studies involving:
- Pediatric safety monitoring and regulatory guidance
- Early-phase adaptive trial designs
- Long-term follow-up and post-marketing surveillance
- Coordination across hospitals, imaging vendors, and specialty labs
Our model integrates medical monitoring, study physician oversight, and strategic site support, ensuring every step is optimized for both sponsor goals and patient care.
Looking for Deep Expertise in Pediatric Oncology?
Work with a CRO that truly understands the urgency and complexity of neuroblastoma research. At Ergomed, we combine scientific rigor with compassionate care to support children and families facing rare cancers. Our teams bring hands-on experience across Phase I–III pediatric oncology studies, including dose-escalation, adaptive, and cohort-based trial designs.